Supply and Clinical Application of Actinium-225 and Bismuth-213

The recent development of (225)Ac-PSMA617 for therapy of prostate cancer has strikingly demonstrated the clinical potential of targeted alpha therapy. Further promising applications of the alpha emitters (225)Actinium and its daughter nuclide (213)Bismuth include the therapy of brain tumors, bladder cancer, neuroendocrine tumors, and leukemia. This paper will provide a brief overview on the current status of the clinical development of compounds labelled with (225)Ac or (213)Bi and describe the various production routes that are in place or are under development to meet the increasing demand for these radionuclides.